Conflict Of Interest Policies Research Articles

EWSR1-PATZ1 Fusion Gene in Ependymoma: A Report of Two Adult Cases and Systematic Review of Literature

Article Tools CASE REPORTS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/PO.22.00312 JCO Precision Oncology no. 6 (2022) e2200312. Published online December 8, 2022. PMID: 36480780 EWSR1-PATZ1 Fusion Gene in Ependymoma: A Report of Two Adult Cases and Systematic Review of Literature Sandesh Reddy, BS1xSandesh ReddySearch for articles by this author; Alex Flores, MD1xAlex FloresSearch for articles by this author; Sungho Lee, MD, PhD1xSungho LeeSearch for articles by this author; Arya Shetty , BA1xArya ShettySearch for articles by this author; Darsh Shah, BS2xDarsh ShahSearch for articles by this author; Kent A. Heck, MD3xKent A. HeckSearch for articles by this author; Ali Jalali , MD, PhD1xAli JalaliSearch for articles by this author; Jacob J. Mandel , MD4xJacob J. MandelSearch for articles by this author; and Akash J. Patel , MD1,5,6xAkash J. PatelSearch for articles by this author Show More 1Department of Neurological Surgery, Baylor College of Medicine, Houston, TX2Department of Neurological Surgery, Dell Medical School, Austin, TX3Department of Pathology, Baylor College of Medicine, Houston, TX4Department of Neurology, Baylor College of Medicine, Houston, TX5Department of Otolaryngology-Head and Neck Surgery, Baylor College of Medicine, Houston, TX6Jan and Dan Duncan Neurological Research Institute, Texas Children's Hospital, Houston, TX https://doi.org/10.1200/PO.22.00312 First Page Full Text PDF Figures and Tables © 2022 by American Society of Clinical OncologyAUTHOR CONTRIBUTIONSConception and design: Alex Flores, Sungho Lee, Darsh Shah, Jacob J. Mandel, Akash J. PatelProvision of study materials or patients: Jacob J. MandelCollection and assembly of data: Sandesh Reddy, Alex Flores, Arya Shetty, Kent A. Heck, Jacob J. Mandel, Akash J. PatelData analysis and interpretation: Sandesh Reddy, Arya Shetty, Ali Jalali, Jacob J. Mandel, Akash J. PatelManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Sandesh ReddyPatents, Royalties, Other Intellectual Property: Baylor College of Medicine—Patent pending for medical device pertaining to the transoral thyroidectomy procedure, no financial stakeAlex FloresPatents, Royalties, Other Intellectual Property: Provisional patent (2022-2023): A Computer Vision Approach to Identifying the Manufacturer of Posterior Thoracolumbar Instrumentation Systems (Provisional patent, 1 year)No other potential conflicts of interest were reported.

Content and strength of conflict of interest policies at Scandinavian medical schools: a cross sectional study

BackgroundConcerns around staffs’ and students’ interactions with commercial entities, for example drug companies, have led several North American medical schools to implement conflict of interest (COI) policies. However, little is known about COI policies at European medical schools. We analysed the content and strength of COI policies at Scandinavian medical schools.MethodsWe searched the websites of medical schools in Denmark, Norway, and Sweden and emailed the Deans for additional information. Using comparable methodology to previous studies, the strength of the COI policies was rated on a scale from 0 to 2 across 11 items (higher score more restrictive); we also assessed the presence of oversight mechanisms and sanctions.ResultsWe identified 77 unique policies for 15 medical schools (range 2–8 per school). Most of the policies (n = 72; 94%) were University wide and only five (6%) were specific for the medical schools. For six of eleven items one or more schools had a restrictive policy (score of two). None of the schools had a restrictive policy for the five additional items (speaking relationships, sales representatives, on-site education activities, medical school curriculum, and drug samples). Honoraria was the item with the highest score, with eight of the 15 schools having a score of two. Thirteen of the 15 schools had policies that identified a party responsible for policy oversight and mentioned sanctions for non-compliance.ConclusionOur study provides the first evaluation of all Scandinavian medical schools’ COI policies. We found that the content of COI policies varies widely and still has shortcomings. We encourage Scandinavian medical schools to develop more stringent COI policies to regulate industry interactions with both faculty and students.

Efficacy of Legal Reforms in Managing Conflict of Interest

Managing conflict of interest in the public sector has been and will always be a concern for governments the world over. This is accentuated for several African countries which continue to rank highly on the corruption and bribery indices. Corruption is closely connected to the issue of conflict of interest and consequently, it is important to seek best practices in place to deal effectively with conflict of interest in the public sector. Various tools and legal instruments have been developed by regional and global organizations with the singular aim of aiding their member states to review and modernise their conflict of interest policies. Some African states have either adopted these instruments as forming part of their municipal law or legislated laws on conflict of interest. This article examines the role played by law in defining and regulating conflict of interest and how conflict of interest affects the public sector in Africa. It focuses on how law can be deployed effectively as a tool of establishing governance structures that maintain a culture that minimizes and manages the occurrence of conflict of interest.

Exploring the Next Frontier in Non-Small-Cell Lung Cancer With High MET and Mutated Epidermal Growth Factor Receptor.

Article Tools UNDERSTANDING THE PATHWAY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein–Expressing Non–Small-Cell Lung Cancer. October 26, 2022 ARTICLE CITATION DOI: 10.1200/JCO.22.02086 Journal of Clinical Oncology - published online before print November 3, 2022 PMID: 36331252 Exploring the Next Frontier in Non–Small-Cell Lung Cancer With High MET and Mutated Epidermal Growth Factor Receptor Martin Sattler , PhD1,2xMartin SattlerSearch for articles by this author and Ravi Salgia , MD, PhD3xRavi SalgiaSearch for articles by this author Show More 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA2Department of Medicine, Harvard Medical School, Boston, MA3Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA https://doi.org/10.1200/JCO.22.02086 First Page Full Text PDF Figures and Tables © 2022 by American Society of Clinical OncologyAUTHOR CONTRIBUTIONSConception and design: All authorsManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTExploring the Next Frontier in Non–Small-Cell Lung Cancer With High MET and Mutated Epidermal Growth Factor ReceptorThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Ravi SalgiaConsulting or Advisory Role: Iovance Biotherapeutics, AbbVie, Novartis, AstraZenecaSpeakers' Bureau: AstraZeneca, MerckNo other potential conflicts of interest were reported. Companion Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein–Expressing Non–Small-Cell Lung Cancer

The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission.

The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission.

The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission.

The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission.

The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission.

The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission.

Response to MEK Inhibitor Therapy in MAP2K1 (MEK1) K57N Non-Small-Cell Lung Cancer and Genomic Landscape of MAP2K1 Mutations in Non-Small-Cell Lung Cancer.

Article Tools CASE REPORTS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/PO.22.00382 JCO Precision Oncology no. 6 (2022) e2200382. Published online December 1, 2022. PMID: 36455195 Response to MEK Inhibitor Therapy in MAP2K1 (MEK1) K57N Non–Small-Cell Lung Cancer and Genomic Landscape of MAP2K1 Mutations in Non–Small-Cell Lung Cancer Michael L. Cheng , MD1,2,3xMichael L. ChengSearch for articles by this author; Jessica K. Lee , MS4xJessica K. LeeSearch for articles by this author; Rachit Kumar, MD5xRachit KumarSearch for articles by this author; Harry Klein , PhD6xHarry KleinSearch for articles by this author; Kira Raskina , MD4xKira RaskinaSearch for articles by this author; Alexa B. Schrock , PhD4xAlexa B. SchrockSearch for articles by this author; Kesi S. Michael , BS1,7xKesi S. MichaelSearch for articles by this author; Tali Mazor , PhD6xTali MazorSearch for articles by this author; Ethan Cerami, PhD6xEthan CeramiSearch for articles by this author; Geoffrey R. Oxnard , MD4xGeoffrey R. OxnardSearch for articles by this author; David Liu , MD, MPH, MS2xDavid LiuSearch for articles by this author; Himisha Beltran , MD2xHimisha BeltranSearch for articles by this author; Lynette M. Sholl , MD8xLynette M. ShollSearch for articles by this author; Mizuki Nishino , MD, MPH9,10xMizuki NishinoSearch for articles by this author; and Pasi A. Jänne , MD, PhD1,2,11xPasi A. JänneSearch for articles by this author Show More 1Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA2Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA3Present address: Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA4Foundation Medicine, Cambridge, MA5Harold Alfond Center for Cancer Care, MaineHealth, Augusta, MA6Department of Data Science, Dana-Farber Cancer Institute, Boston, MA7Present address: Foundation Medicine, Cambridge, MA8Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA9Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA10Department of Imaging, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA11Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA https://doi.org/10.1200/PO.22.00382 First Page Full Text PDF Figures and Tables © 2022 by American Society of Clinical OncologySUPPORTM.L.C. was supported by a Conquer Cancer Foundation—American Society of Clinical Oncology Career Development Award.AUTHOR CONTRIBUTIONSConception and design: Michael L. Cheng, Mizuki Nishino, Pasi A. JänneProvision of study materials or patients: Rachit KumarCollection and assembly of data: Michael L. Cheng, Rachit Kumar, Kesi S Michael, Tali Mazor, Ethan Cerami, Lynette M. Sholl, Mizuki NishinoData analysis and interpretation: Michael L. Cheng, Jessica K. Lee, Harry Klein, Kira Raskina, Alexa B. Schrock, Ethan Cerami, Geoffrey R. Oxnard, David Liu, Himisha Beltran, Lynette M. Sholl, Mizuki NishinoManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Michael L. ChengHonoraria: Lynx Group, WebMD, Potomac Center for Medical EducationConsulting or Advisory Role: AstraZeneca, Inivata, Boehringer Ingelheim, Mirati TherapeuticsResearch Funding: Palleon Pharmaceuticals (Inst)Travel, Accommodations, Expenses: Daiichi Sankyo, AstraZeneca, GenzymeJessica K. LeeEmployment: Foundation MedicineStock and Other Ownership Interests: RocheKira RaskinaEmployment: Foundation MedicineStock and Other Ownership Interests: RocheResearch Funding: Foundation MedicineAlexa B. SchrockEmployment: Foundation MedicineStock and Other Ownership Interests: Foundation Medicine, RocheKesi S. MichaelEmployment: Foundation MedicineStock and Other Ownership Interests: Roche/GenentechEthan CeramiConsulting or Advisory Role: Third Rock VenturesGeoffrey R. OxnardEmployment: Foundation MedicineStock and Other Ownership Interests: RocheHimisha BeltranConsulting or Advisory Role: Janssen Oncology, AstraZeneca, Pfizer, Blue Earth Diagnostics, Foundation Medicine, Amgen, Loxo/LillyResearch Funding: Janssen (Inst), AbbVie/Stemcentrx (Inst), Bristol Myers Squibb Foundation (Inst)Travel, Accommodations, Expenses: Janssen OncologyLynette M. ShollStock and Other Ownership Interests: Moderna TherapeuticsConsulting or Advisory Role: Genentech (Inst), Lilly (Inst)Research Funding: Roche/Genentech (Inst)Mizuki NishinoConsulting or Advisory Role: Daiichi Sankyo, AstraZenecaResearch Funding: Toshiba (Inst), AstraZeneca (Inst), Daiichi Sankyo (Inst)Pasi A. JänneStock and Other Ownership Interests: Gatekeeper Pharmaceuticals, LoxoConsulting or Advisory Role: Pfizer, Boehringer Ingelheim, AstraZeneca, Merrimack, Chugai Pharma, Roche/Genentech, LOXO, Mirati Therapeutics, Araxes Pharma, Ignyta, Lilly, Takeda, Novartis, Biocartis, Voronoi Health Analytics, SFJ Pharmaceuticals Group, Sanofi, Daiichi Sankyo, Silicon Therapeutics, Nuvalent, Inc, Eisai, Bayer, Syndax, AbbVie, Allorion Therapeutics, Accutar Biotech, TranscentaResearch Funding: AstraZeneca, Astellas Pharma, Daiichi Sankyo, Lilly, Boehringer Ingelheim, Puma Biotechnology, Takeda, Revolution MedicinesPatents, Royalties, Other Intellectual Property: I am a coinventor on a DFCI-owned patent on EGFR mutations licensed to Lab Corp. I receive postmarketing royalties from this inventionNo other potential conflicts of interest were reported.

Use of Erdafitinib in FGFR3-Mutated Recurrent Respiratory Papillomatosis.

Article Tools CASE REPORTS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/PO.22.00435 JCO Precision Oncology no. 6 (2022) e2200435. Published online December 1, 2022. Use of Erdafitinib in FGFR3-Mutated Recurrent Respiratory Papillomatosis Vincent Yeung , MD1xVincent YeungSearch for articles by this author; Paul Sackstein , MD2xPaul SacksteinSearch for articles by this author; Nazaneen N. Grant, MD3xNazaneen N. GrantSearch for articles by this author; Rebecca Krochmal, MD4xRebecca KrochmalSearch for articles by this author; Nishant Gandhi, PhD5xNishant GandhiSearch for articles by this author; Charu Aggarwal , MD6xCharu AggarwalSearch for articles by this author; Balazs Halmos , MD7xBalazs HalmosSearch for articles by this author; Joshua E. Reuss , MD1xJoshua E. ReussSearch for articles by this author; Stephen V. Liu , MD1xStephen V. LiuSearch for articles by this author; and Chul Kim , MD1xChul KimSearch for articles by this author Show More 1Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC2Department of Internal Medicine, Georgetown University, Washington, DC3Department of Otolaryngology, Georgetown University, Washington, DC4Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, Georgetown University, Washington, DC5Medical Affairs, Caris Life Sciences, Phoenix, AZ6Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA7Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY https://doi.org/10.1200/PO.22.00435 First Page Full Text PDF Figures and Tables © 2022 by American Society of Clinical OncologyAUTHOR CONTRIBUTIONSConception and design: Vincent Yeung, Rebecca Krochmal, Charu Aggarwal, Stephen V. Liu, Chul KimAdministrative support: Chul KimProvision of study materials or patients: Chul KimCollection and assembly of data: Vincent Yeung, Nazaneen N. Grant, Nishant Gandhi, Stephen V. Liu, Chul KimData analysis and interpretation: Vincent Yeung, Paul Sackstein, Rebecca Krochmal, Nishant Gandhi, Balazs Halmos, Joshua E. Reuss, Stephen V. Liu, Chul KimManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Rebecca KrochmalHonoraria: Intuitive SurgicalTravel, Accommodations, Expenses: Intuitive SurgicalNishant GandhiEmployment: Caris Life SciencesCharu AggarwalConsulting or Advisory Role: Genentech, Lilly, Celgene, Merck, AstraZeneca, Blueprint Genetics, Shionogi, Daiichi Sankyo/Astra Zeneca, Sanofi/Regeneron, Eisai, BeiGene, Turning Point Therapeutics, Pfizer, Janssen, Boehringer IngelheimSpeakers' Bureau: AstraZeneca (I), Roche/Genentech (I)Research Funding: Genentech/Roche (Inst), Incyte (Inst), Macrogenics (Inst), Merck Sharp & Dohme (Inst), AstraZeneca/MedImmune (Inst)Balazs HalmosConsulting or Advisory Role: AstraZeneca, Boehringer Ingelheim, Genentech/Roche, Pfizer, Takeda, Novartis, Merck, Bristol Myers Squibb, Turning Point Therapeutics, Apollomics, Janssen Oncology, Veracyte, BeiGene, Arcus BiosciencesResearch Funding: Merck (Inst), AstraZeneca (Inst), Mirati Therapeutics (Inst), Boehringer Ingelheim (Inst), Roche/Genentech (Inst), Pfizer (Inst), Takeda (Inst), AbbVie (Inst), Bristol Myers Squibb (Inst), GlaxoSmithKline (Inst), Blueprint Medicines (Inst), Novartis (Inst), Advaxis (Inst), Janssen Oncology (Inst), Elevation Oncology (Inst), Amgen (Inst), BeiGene (Inst), Daiichi Sankyo/Astra Zeneca (Inst)Joshua E. ReussHonoraria: AstraZeneca/MedImmuneConsulting or Advisory Role: OncoCyte, Genentech/Roche, Sanofi, Personalis, Guardant HealthResearch Funding: Genentech/Roche (Inst), Verastem (Inst)Stephen V. LiuConsulting or Advisory Role: Genentech, Lilly, Bristol Myers Squibb, AstraZeneca, Takeda, Regeneron, Guardant Health, Janssen Oncology, MSD Oncology, Jazz Pharmaceuticals, Blueprint Medicines, Daiichi Sankyo/UCB Japan, BeiGene, Amgen, Turning Point Therapeutics, Elevation Oncology, Novartis, Eisai, Bayer, Gilead Sciences, SanofiResearch Funding: Genentech/Roche (Inst), Pfizer (Inst), Bayer (Inst), Merck (Inst), Blueprint Medicines (Inst), Lilly (Inst), Rain Therapeutics (Inst), Alkermes (Inst), Bristol Myers Squibb (Inst), Turning Point Therapeutics (Inst), RAPT Therapeutics (Inst), Merus (Inst), Elevation Oncology (Inst), Nuvalent, Inc (Inst), Gilead Sciences (Inst)Travel, Accommodations, Expenses: Caris Life SciencesChul KimConsulting or Advisory Role: Janssen, Novartis, PierianDx, AstraZeneca, Sanofi, Diffusion Pharmaceuticals, Mirati Therapeutics, Jazz Pharmaceuticals, Arcus BiosciencesResearch Funding: AstraZeneca, Novartis, Karyopharm Therapeutics, Bristol Myers Squibb, Regeneron, Debiopharm Group, Janssen, Genentech/RocheNo other potential conflicts of interest were reported.

Exquisitely Platinum-Sensitive Triple-Negative Breast Cancer, Time for BRCA Methylation Testing?

Article Tools CASE REPORTS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/PO.22.00309 JCO Precision Oncology no. 6 (2022) e2200309. Published online November 3, 2022. PMID: 36331241 Exquisitely Platinum-Sensitive Triple-Negative Breast Cancer, Time for BRCA Methylation Testing? Tira J. Tan , MBBS1,2xTira J. TanSearch for articles by this author; J. Lynn Fink, PhD3,4xJ. Lynn FinkSearch for articles by this author; Timothy K. Tay , MBBS5xTimothy K. TaySearch for articles by this author; Binny Jaradi , BSc3xBinny JaradiSearch for articles by this author; Nathan Stone, BBiotech3xNathan StoneSearch for articles by this author; Paul Waring , MBBS, PhD3xPaul WaringSearch for articles by this author; Kevin M. Koo , PhD3xKevin M. KooSearch for articles by this author; Puay Hoon Tan, MBBS, MD5xPuay Hoon TanSearch for articles by this author; Daniel S. Tan , PhD1,2xDaniel S. TanSearch for articles by this author; and Rebecca A. Dent, MD1,2xRebecca A. DentSearch for articles by this author Show More 1Division of Medical Oncology, National Cancer Centre, Singapore, Singapore2Oncology Academic Clinical Program, Duke-NUS Medical School, Singapore, Singapore3XING Genomic Services, Brisbane, Australia4The University of Queensland Diamantina Institute, Brisbane, Australia5Division of Pathology, Singapore General Hospital, Singapore, Singapore https://doi.org/10.1200/PO.22.00309 First Page Full Text PDF Figures and Tables © 2022 by American Society of Clinical OncologySUPPORTT.J.T. is supported by the NMRC research training fellowship. XING Genomic Services provided the oncoReveal assays used in this case report.AUTHOR CONTRIBUTIONSConception and design: Tira J. Tan, J. Lynn Fink, Rebecca A. DentFinancial support: Daniel S. TanAdministrative support: Tira J. Tan, J. Lynn Fink, Timothy K. Tay, Kevin M. Koo, Rebecca A. DentProvision of study materials or patients: Tira J. Tan, J. Lynn Fink, Timothy K. Tay, Paul Waring, Puay Hoon Tan, Rebecca A. DentCollection and assembly of data: Tira J. Tan, J. Lynn Fink, Timothy K. Tay, Binny Jaradi, Nathan Stone, Paul Waring, Rebecca A. DentData analysis and interpretation: Tira J. Tan, J. Lynn Fink, Paul Waring, Kevin M. Koo, Puay Hoon Tan, Daniel S. Tan, Rebecca A. DentManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Tira J. TanHonoraria: AstraZeneca, Roche/Genentech, Novartis, MSD OncologyConsulting or Advisory Role: AstraZeneca, Lilly, Novartis, MSD Oncology, Everest Medicine, DKSHSpeakers' Bureau: NovartisResearch Funding: Bayer (Inst), Novartis (Inst), AstraZeneca (Inst), Odonate Therapeutics (Inst), Seattle Genetics (Inst), Roche/Genentech (Inst), Daiichi Sankyo/Astra Zeneca (Inst), Sanofi (Inst)Travel, Accommodations, Expenses: AstraZenecaJ. Lynn FinkEmployment: Xing TechnologiesStock and Other Ownership Interests: Xing TechnologiesPaul WaringEmployment: AstraZenecaLeadership: Pillar Biosciences, Xing Technologies, ORI healthcareStock and Other Ownership Interests: Roche/Genentech, Roche, Pillar Biosciences, Xing TechnologiesConsulting or Advisory Role: Pillar Biosciences, Xing Technologies, ORI HealthcareTravel, Accommodations, Expenses: Xing Technologies, AstraZenecaKevin M. KooEmployment: Xing TechnologiesLeadership: Xing TechnologiesPuay Hoon TanHonoraria: AstraZenecaConsulting or Advisory Role: AstraZenecaDaniel S. TanHonoraria: Bristol Myers Squibb, Takeda, Novartis, Roche, PfizerConsulting or Advisory Role: Novartis, Merck, Loxo, AstraZeneca, Roche, Pfizer, C4 TherapeuticsResearch Funding: Novartis (Inst), GlaxoSmithKline (Inst), AstraZeneca (Inst)Travel, Accommodations, Expenses: Pfizer, Boehringer Ingelheim, RocheRebecca A. DentHonoraria: Roche/Genentech, AstraZeneca, Pfizer, MSD, Eisai Europe, LillyConsulting or Advisory Role: Roche, Pfizer, Merck, Eisai, AstraZeneca, NovartisResearch Funding: AstraZeneca, RocheTravel, Accommodations, Expenses: Roche, Pfizer, Amgen, Merck, AstraZenecaNo other potential conflicts of interest were reported.

The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission.

The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission.

The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission.

The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission.

Outcomes After Retreatment With Inotuzumab Ozogamicin for Relapsed/Refractory Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia.

Article Tools CASE REPORTS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/PO.22.00353 JCO Precision Oncology no. 6 (2022) e2200353. Published online October 14, 2022. PMID: 36240471 Outcomes After Retreatment With Inotuzumab Ozogamicin for Relapsed/Refractory Philadelphia Chromosome–Negative B-Cell Acute Lymphoblastic Leukemia Juan Alban , MD1xJuan AlbanSearch for articles by this author; Adam DuVall , MD, MPH2xAdam DuVallSearch for articles by this author; Sandeep Gurbuxani , MBBS3xSandeep GurbuxaniSearch for articles by this author; Wendy Stock , MD2xWendy StockSearch for articles by this author; and Anand Ashwin Patel , MD2xAnand Ashwin PatelSearch for articles by this author Show More 1Department of Medicine, University of Chicago, Chicago, IL2Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL3Section of Hematopathology, Department of Pathology, University of Chicago, Chicago, IL https://doi.org/10.1200/PO.22.00353 First Page Full Text PDF Figures and Tables Supplements © 2022 by American Society of Clinical OncologyAUTHOR CONTRIBUTIONSConception and design: All authorsCollection and assembly of data: Juan Alban, Sandeep Gurbuxani, Anand Ashwin PatelData analysis and interpretation: All authorsManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Juan AlbanEmployment: AbbVie (I)Leadership: AbbVie (I), SpringWorks Therapeutics (I)Adam DuVallConsulting or Advisory Role: Jazz PharmaceuticalsSpeakers' Bureau: Jazz PharmaceuticalsSandeep GurbuxaniConsulting or Advisory Role: AbbViePatents, Royalties, Other Intellectual Property: Royalties from UpToDate for contributions to various topicsWendy StockHonoraria: AbbVie, PfizerConsulting or Advisory Role: Jazz Pharmaceuticals, Kite, a Gilead Company, Kura Oncology, GlaxoSmithKline, Morphosys, Pfizer, Servier, Deciphira, BEAm, Newave Pharmaceutical, AstraZeneca, Kronos Bio, Pluristem TherapeuticsPatents, Royalties, Other Intellectual Property: Royalties for a chapter in Up to DateTravel, Accommodations, Expenses: PfizerAnand Ashwin PatelResearch Funding: Bristol Myers Squibb/Celgene (Inst), Servier (Inst), Pfizer (Inst)No other potential conflicts of interest were reported.

Development processes for e-cigarette public health recommendations lacked transparency in managing conflicts of interest

ObjectivesTo investigate how guideline development groups collect and manage conflicts of interest (COI) when producing electronic cigarette (e-cigarette) recommendations. Study Design and SettingPublic health bodies that had produced e-cigarette recommendations were identified from four purposively selected jurisdictions (World Health Organization, United Kingdom, Australia, and United States). We analysed their COI policies and conducted 15 interviews with guideline methodologists, policymakers, and academics in guideline development groups. ResultsOnly five of 10 public health bodies had a publicly available COI policy. Participants discussed the importance of those involved in the development process declaring COI. However, there were differences in who had to report COI, the time period asked about, and what and how declarations are made. COI policies and participants discussed a range of approaches for managing COI, from limiting involvement to disqualification from the recommendation development process. Participants considered the current processes for collecting and managing COI insufficient due to their open interpretation and possibility for partial declarations of interest. ConclusionThe management of COI varies across public health bodies, with little standardization and lack of transparency. To improve the collection and management of COI, and ultimately increase the trustworthiness of recommendations, guideline development groups should draw upon a comprehensive and accessible COI policy.

Minus Times Minus Equals Plus

Article Tools UNDERSTANDING THE PATHWAY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non–Small-Cell Lung Cancer. April 22, 2022 ARTICLE CITATION DOI: 10.1200/JCO.22.01112 Journal of Clinical Oncology - published online before print August 18, 2022 PMID: 35981269 Minus Times Minus Equals Plus John B.A.G. Haanen , PhD, MD1xJohn B.A.G. HaanenSearch for articles by this author; and Solange Peters , PhD, MD2xSolange PetersSearch for articles by this author Show More 1Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands2Chair Medical Oncology, Oncology Department—CHUV, Lausanne, Switzerland https://doi.org/10.1200/JCO.22.01112 First Page Full Text PDF Figures and Tables © 2022 by American Society of Clinical OncologyAUTHOR CONTRIBUTIONSConception and design: All authorsCollection and assembly of data: All authorsData analysis and interpretation: All authorsManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTMinus Times Minus Equals PlusThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).John B.A.G. HaanenStock and Other Ownership Interests: Neogene TherapeuticsConsulting or Advisory Role: MSD Oncology (Inst), Pfizer (Inst), Bristol Myers Squibb (Inst), Novartis (Inst), Roche/Genentech (Inst), Ipsen (Inst), Achilles Therapeutics (Inst), Immunocore (Inst), Sanofi (Inst), Third Rock Ventures (Inst), Neogene Therapeutics, Molecular Partners (Inst), BioNTech (Inst), T-Knife (Inst), PokeAcell (Inst), Instil Bio (Inst), Iovance Biotherapeutics (Inst)Research Funding: MSD (Inst), Bristol Myers Squibb (Inst), Novartis (Inst), Neon Therapeutics (Inst), Amgen (Inst), BioNTech (Inst), Asher Biotherapeutics (Inst)Solange PetersHonoraria: Roche (Inst), Bristol Myers Squibb (Inst), Novartis (Inst), Pfizer (Inst), MSD (Inst), AstraZeneca (Inst), Takeda (Inst), Illumina (Inst), Medscape (Inst), Prime Oncology (Inst), RMEI Medical Education (Inst), Research to Practice (Inst), PER (Inst), Imedex (Inst), ecancer (Inst), Oncology Education (Inst), Fishawack Facilitate (Inst)Consulting or Advisory Role: Roche/Genentech (Inst), Novartis (Inst), Bristol Myers Squibb (Inst), Pfizer (Inst), MSD (Inst), Amgen (Inst), AstraZeneca (Inst), Janssen (Inst), Regeneron (Inst), Merck Serono (Inst), Boehringer Ingelheim (Inst), Takeda (Inst), Lilly (Inst), AbbVie (Inst), Bayer (Inst), Biocartis (Inst), Debiopharm Group (Inst), Illumina (Inst), PharmaMar (Inst), Sanofi (Inst), Seattle Genetics (Inst), Blueprint Medicines (Inst), Daiichi Sankyo (Inst), Incyte (Inst), BioInvent (Inst), Clovis Oncology (Inst), Vaccibody (Inst), Phosplatin Therapeutics (Inst), Foundation Medicine (Inst), Arcus Biosciences (Inst), F-Star Biotechnology (Inst), Genzyme (Inst), Gilead Sciences (Inst), GlaxoSmithKline (Inst)Research Funding: Roche (Inst), BMS (Inst), MSD (Inst), Amgen (Inst), Lilly (Inst), AstraZeneca (Inst), Pfizer (Inst), Illumina (Inst), Merck Serono (Inst), Novartis (Inst), Biodesix (Inst), Boehringer Ingelheim (Inst), Iovance Biotherapeutics (Inst), Phosplatin Therapeutics (Inst)Travel, Accommodations, Expenses: Roche, Bristol Myers Squibb, MSD, Sanofi, IncyteUncompensated Relationships: Journal of Thoracic Oncology, ESMO, European Thoracic Oncology Platform (ETOP), Annals of OncologyNo other potential conflicts of interest were reported. Companion COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non–Small-Cell Lung Cancer

Examination of Potential Industry Conflicts of Interest and Disclosures by Contributors to Online Medical Resource Databases

Physicians contribute content to online databases, and other health care professionals use these websites to support their decision-making. Financial conflicts of interest (COI) have the potential to adversely impact evidence-based patient care. To quantify the potential COI among content contributors to 2 popular point-of-care medical resources, UpToDate and DynaMed, overall and by gender, and to compare self-reported and industry-mandated disclosures. This cross-sectional study compiled an initial list of contributors for each website using the Centers for Disease Control and Prevention's Leading Causes of Death. The top 50 causes were used to identify relevant articles from each database from November 30 to December 7, 2020. The authors and editors of those articles were investigated. Data were analyzed from January 2021 to March 2022. Self-reported contributor disclosure status was compared with financial remuneration as reported in the Centers for Medicare & Medicaid Services Open Payments (OP) database from 2013 to 2018. A total of 179 point-of-care database authors and editors were assessed. Combined, they received $77.7 million, with a mean of $583 218 (95% CI, $0-$4 679 651) and median (range) of $29 073 ($10-$17 517 315) each. Most of the compensation ($68.1 million [87.6%]) went to UpToDate contributors. Of 128 UpToDate contributors, 76 (59.4%) reported nothing to disclose, and among these, 44 contributors (57.9%) had a record of receiving a financial payment on OP. Women UpToDate contributors received 2.5% of the total compensation paid from industry. The top 10 UpToDate contributors who received the most financial remuneration earned $56.1 million combined, were all men, and only 1 had a nothing-to-disclose status. Of 51 DynaMed contributors, 42 (82.4%) reported nothing to disclose, and among these, 35 contributors (83.3%) had an OP entry (mean, $79 820; 95% CI, $0-$400 774; median [range], $1403 [$26-$630 424]). Among the top 10 DynaMed contributors, 8 (80.0%) were men. Six of the top 10 DynaMed contributors reported nothing to disclose yet had an OP entry. This cross-sectional study found that contributors to point-of-care databases were the recipients of nearly $78 million from pharmaceutical companies and medical device manufacturers, and these payments were often not disclosed in association with contributed content. Although these findings do not necessarily suggest ethical lapses among the physicians studied, point-of-care resource websites, like UpToDate and DynaMed, should consider implementing more stringent COI policies and employ an unbiased team to verify self-reported disclosure statuses among content contributors against OP reports.

BRCA2 Alterations in Neuroendocrine/Small-Cell Carcinoma Prostate Cancer: A Case Series.

Article Tools CASE REPORTS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/PO.22.00091 JCO Precision Oncology no. 6 (2022) e2200091. Published online July 14, 2022. PMID: 35834759 BRCA2 Alterations in Neuroendocrine/Small-Cell Carcinoma Prostate Cancer: A Case Series Lynn Symonds , MD1xLynn SymondsSearch for articles by this author; Erik Konnick , MD2xErik KonnickSearch for articles by this author; Funda Vakar-Lopez, MD2xFunda Vakar-LopezSearch for articles by this author; Heather H. Cheng , MD, PhD1,3xHeather H. ChengSearch for articles by this author; Michael T. Schweizer , MD1,3xMichael T. SchweizerSearch for articles by this author; Peter S. Nelson , MD1,2,3,4xPeter S. NelsonSearch for articles by this author; Colin C. Pritchard , MD, PhD2,5xColin C. PritchardSearch for articles by this author; and Bruce Montgomery , MD1,6xBruce MontgomerySearch for articles by this author Show More 1Division of Medical Oncology, University of Washington, Seattle, WA2Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA3Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA4Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, WA5Brotman Baty Institute for Precision Medicine, Seattle, WA6VA Puget Sound and Precision Oncology Program for Cancer of the Prostate, Seattle, WA https://doi.org/10.1200/PO.22.00091 First Page Full Text PDF Figures and Tables © 2022 by American Society of Clinical OncologySUPPORTSupported by the Pacific Northwest Prostate Cancer SPORE CA097186 (P.S.N., B.M.); Prostate Cancer Foundation Challenge Awards (B.M., P.S.N.); CDMRP Awards W81XWH-18-1-0355 (P.S.N., C.C.P., B.M.), W81XWH-21-1-0264 (P.S.N.), W81XWH-17-2-0043 (H.H.C.), R01 CA234715 (P.S.N.), T32 CA009515 (L.S.).AUTHOR CONTRIBUTIONSConception and design: Peter S. Nelson, Bruce MontgomeryFinancial support: Peter S. NelsonAdministrative support: Bruce MontgomeryProvision of study materials or patients: Funda Vakar-Lopez, Heather H. Cheng, Peter S. Nelson, Colin C. PritchardCollection and assembly of data: Erik Konnick, Funda Vakar-Lopez, Heather H. Cheng, Colin C. Pritchard, Bruce MontgomeryData analysis and interpretation: Lynn Symonds, Erik Konnick, Heather H. Cheng, Michael T. Schweizer, Peter S. Nelson, Colin C. Pritchard, Bruce MontgomeryManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Erik KonnickConsulting or Advisory Role: RocheFunda Vakar-LopezConsulting or Advisory Role: AstraZenecaHeather H. ChengConsulting or Advisory Role: AstraZeneca, AstraZeneca (I)Research Funding: Sanofi (Inst), Janssen (Inst), Clovis Oncology (Inst), Color Genomics Foundation (Inst), Medivation/Astellas (Inst), Phosplatin Therapeutics (Inst)Patents, Royalties, Other Intellectual Property: UpToDateOther Relationship: JanssenMichael T. SchweizerConsulting or Advisory Role: Resverlogix, AstraZeneca, PharmaIn, SanofiResearch Funding: Janssen (Inst), AstraZeneca (Inst), Roche (Inst), Pfizer (Inst), Zenith Epigenetics (Inst), Madison Vaccines, Inc (Inst), Immunomedics (Inst), Bristol Myers Squibb (Inst), Merck (Inst), Tmunity Therapeutics, Inc (Inst), SignalOne Bio (Inst)Peter S. NelsonConsulting or Advisory Role: Janssen Oncology, Astellas Pharma, Roche/Genentech, Bristol Myers SquibbResearch Funding: Genomic Health (Inst)Expert Testimony: VenableTravel, Accommodations, Expenses: Janssen OncologyColin C. PritchardConsulting or Advisory Role: AstraZeneca, Sana BiotechnologyResearch Funding: Color Genomics (I)Bruce MontgomeryResearch Funding: AstraZeneca (Inst), Janssen Oncology (Inst), Clovis Oncology (Inst), Astellas Pharma (Inst), Beigene (Inst)No other potential conflicts of interest were reported.

Associations Between Aggregate NLP-Extracted Conflicts of Interest and Adverse Events by Drug Product.

This study evaluates associations between aggregate conflicts of interest (COI) and drug safety. We used a machine-learning system to extract and classify COI from PubMed-indexed disclosure statements. Individual conflicts were classified as Type 1 (personal fees, travel, board memberships, and non-financial support), Type 2 (grants and research support), or Type 3 (stock ownership and industry employment). COI were aggregated by type compared to adverse events by product. Type 1 COI are associated with a 1.1-1.8% increase in the number of adverse events, serious events, hospitalizations, and deaths. Type 2 COI are associated with a 1.7-2% decrease in adverse events across severity levels. Type 3 COI are associated with an approximately 1% increase in adverse events, serious events, and hospitalizations, but have no significant association with adverse events resulting in death. The findings suggest that COI policies might be adapted to account the relative risks of different types of financial relationships.

Checkpoint Inhibitor Immunotherapy to Treat Temozolomide-Associated Hypermutation in Advanced Atypical Carcinoid Tumor of the Lung.

Article Tools CASE REPORTS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/PO.22.00009 JCO Precision Oncology no. 6 (2022) e2200009. Published online June 23, 2022. PMID: 35737914 Checkpoint Inhibitor Immunotherapy to Treat Temozolomide-Associated Hypermutation in Advanced Atypical Carcinoid Tumor of the Lung Fangdi Sun, MD1xFangdi SunSearch for articles by this author; James P. Grenert, MD, PhD2xJames P. GrenertSearch for articles by this author; Lisa Tan, BS1xLisa TanSearch for articles by this author; Jessica Van Ziffle , PhD2xJessica Van ZiffleSearch for articles by this author; Nancy M. Joseph, MD, PhD2xNancy M. JosephSearch for articles by this author; Claire K. Mulvey , MD1xClaire K. MulveySearch for articles by this author; and Emily Bergsland , MD1xEmily BergslandSearch for articles by this author Show More 1Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, San Francisco, CA2Department of Pathology, University of California, San Francisco, San Francisco, CA https://doi.org/10.1200/PO.22.00009 First Page Full Text PDF Figures and Tables © 2022 by American Society of Clinical OncologySUPPORTSupported by the National Cancer Institute of the National Institutes of Health under award No. P30CA082103.AUTHOR CONTRIBUTIONSConception and design: Fangdi Sun, Emily BergslandCollection and assembly of data: Fangdi Sun, Lisa Tan, Jessica Van ZiffleData analysis and interpretation: Fangdi Sun, James P. Grenert, Nancy M. Joseph, Claire K. Mulvey, Emily BergslandManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Jessica Van ZiffleEmployment: Adaptive Biotechnologies (I)Stock and Other Ownership Interests: Adaptive Biotechnologies (I)Patents, Royalties, Other Intellectual Property: Adaptive Biotechnologies (I)Claire K. MulveyHonoraria: OncLive/MJH Life SciencesResearch Funding: GenentechEmily BergslandStock and Other Ownership Interests: More Health (I), Exai Bio (I)Consulting or Advisory Role: More Health (I)Research Funding: MerckPatents, Royalties, Other Intellectual Property: UpToDateNo other potential conflicts of interest were reported.

Pediatric Acute Myeloid Leukemia Enters the Molecularly Targeted Era Via FLT3 Inhibition

Article Tools UNDERSTANDING THE PATHWAY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio FLT3/ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031. March 29, 2022 ARTICLE CITATION DOI: 10.1200/JCO.22.00499 Journal of Clinical Oncology - published online before print April 18, 2022 PMID: 35436158 Pediatric Acute Myeloid Leukemia Enters the Molecularly Targeted Era Via FLT3 Inhibition Alexander E. Perl , MD1xAlexander E. PerlSearch for articles by this author Show More 1Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA https://doi.org/10.1200/JCO.22.00499 First Page Full Text PDF Figures and Tables © 2022 by American Society of Clinical OncologyAUTHOR'S DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTPediatric Acute Myeloid Leukemia Enters the Molecularly Targeted Era Via FLT3 InhibitionThe following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Alexander E. PerlHonoraria: Astellas Pharma, Daiichi SankyoConsulting or Advisory Role: Astellas Pharma, Actinium Pharmaceuticals, Daiichi Sankyo, AbbVie, FORMA Therapeutics, Sumitomo Dainippon, Celgene/Bristol Myers Squibb, Syndax, Genentech, BerGenBio, ImmunogenResearch Funding: Astellas Pharma (Inst), Bayer (Inst), Daiichi Sankyo (Inst), Fujifilm (Inst), AbbVie (Inst), Syndax (Inst)No other potential conflicts of interest were reported. Companion Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio FLT3/ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031